ASCO 2023 – Meet IDDI Oncology Experts
Publié le
Schedule a meeting with Dr Marc Buyse, ScD and Dr Everardo Saad, MD at ASCO 2023 We will be happy…
Re-Evaluation of Pathologic Complete Response as a Surrogate for Event-Free and Overall Survival in HER2–Positive, Early Breast Cancer Treated With Neoadjuvant Therapy Including Anti–HER2 Therapy
Publié le
Abstract: Purpose Pathologic complete response (pCR) has prognostic importance and is frequently used as a primary end point, but doubts…
Why do so Many Phase III Fail?
Publié le
Randomized controlled trials (RCTs), particularly in phase 3, are the preferred sources of evidence for drug approval and reimbursement decisions….
Assessing treatment efficacy in early-phase oncology trials
Publié le
Join IDDI experts to get updated on efficacy assessment in early-phase trials and more! ABSTRACT: One of the major recent…
Assessing activity in early-phase trials in oncology: current designs for expansion cohorts and phase 2
Publié le
Be updated on different types of Bayesian and frequentist designs that may be used for expansion cohorts in phase 1…
ASSESSING TREATMENT BENEFIT IN IMMUNO-ONCOLOGY
Publié le
This webinar was presented by Laurence Collette, MSc, PhD, Principal Statistician, Consulting Services at IDDI at the 5th Annual Next…
IDDI sponsors the 2nd Annual Dry AMD Therapeutic Development Summit
Publié le
IDDI is a proud sponsor of the 2nd Annual Dry AMD Therapeutic Development Summit! Schedule a meeting with our BD…
Phase I trials in oncology: Pros and cons of current designs
Publié le
Demystifying different types of Bayesian and frequentist designs that may be used for first-in-human or other types of phase I…
Immunotherapy against cancer: Challenge and opportunities
Publié le
With some of the recently developed drugs showing unprecedented response rates and consistent improvement in overall survival in some indications,…
Biostatistics and SARS-CoV-2: research, policymaking, and communication
Publié le
Learn on the central role of Biostatistics in the COVID-19 Pandemia, and the multidisciplinary nature of pandemic response LISTEN TO…